Immune checkpoint blockade for cancer therapy:current progress and perspectives

二维码有效期 120s

摘要Dysfunction of anti-tumor immune responses is crucial for cancer progression.Immune checkpoint blockade(ICB),which can potentiate T cell responses,is an effective strategy for the normalization of host anti-tumor immunity.In recent years,immune checkpoints,expressed on both tumor cells and immune cells,have been identified;some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration(FDA)for clinical treatment.However,limited responses and immune-related adverse events(irAEs)cannot be ignored.This review outlines the development and applications of ICBs,potential strategies for overcoming resistance,and future directions for ICB-based cancer immunotherapy.

作者 Hongying YE ^[1] Weijie LIAO ^[1] Jiongli PAN ^[1] Yin SHI ^[2] Qingqing WANG ^[1] 学术成果认领

作者单位 Institute of Immunology,Zhejiang University School of Medicine,Hangzhou 310058,China;The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province,Hangzhou 310058,China ^[1] Department of Biochemistry,Zhejiang University School of Medicine,Hangzhou 310058,China ^[2]

关键词 Immune checkpoint blockade Cancer immunotherapy Tumor immune evasion Immune normalization

栏目名称

Reviews

DOI 10.1631/jzus.B2300492

发布时间 2025-03-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交